NHS wants a second opinion on Palantir's glowing self-assessments

Palantir Technologies develops software for organising, linking and analysing data from different systems. Its main NHS-related platform is Foundry, which can create a shared operational view from information such as hospital activity, staffing and waiting lists. The supplied article does not cover Palantir or the NHS, so these details come from established public information rather than the source text.

In England, Palantir has been associated with the NHS Federated Data Platform, designed to help organisations use information across institutional boundaries. The software is intended to support planning, coordination and operational decisions. It does not replace clinical judgement or create new patient records by itself; its value depends on the quality, permissions and governance of connected data.

The important issue is therefore not simply what the software is called. NHS organisations must test whether it produces measurable improvements, protects confidentiality and avoids excessive dependence on one supplier. Those questions are not answered by the supplied article and require independent evidence from NHS bodies, auditors and researchers.

Palantir has described its NHS-related software as a way to connect fragmented information and help healthcare organisations coordinate resources. Claimed benefits commonly include clearer operational visibility, better planning, faster responses to bottlenecks and reduced administrative effort. The supplied article contains none of Palantir’s NHS claims, so it cannot establish whether those benefits occurred.

Performance claims should be tied to measurable outcomes. An evaluation might compare waiting times, discharge delays, theatre utilisation, staff workload, data errors and costs before and after deployment. It should also compare similar organisations using different systems, because changes may result from staffing, funding, policy or wider demand rather than software.

The key distinction is between a plausible capability and a demonstrated result. Palantir can explain what its platform is designed to do, but NHS commissioners should require independently reproducible evidence. They should also publish methods, baseline figures, limitations and negative results, rather than relying on vendor-selected examples or testimonials.

The NHS wants an independent second opinion because Palantir benefits commercially when its systems appear effective. A supplier’s internal analysis may be sincere, yet it can still select favourable measures, time periods or examples. Independent scrutiny reduces that risk and gives patients, staff, commissioners and taxpayers a more credible basis for judging the technology.

A proper review would inspect the underlying data, methods, comparison groups and costs. It would ask whether improvements were larger than normal variation and whether similar results could have been achieved more cheaply. It should also examine privacy, security, interoperability, staff experience and the effect of the system on clinical and administrative work.

The supplied article does not mention Palantir or an NHS review. Therefore, it cannot establish the company’s actual claims or the NHS’s stated reasons. In general, however, independent assessment is especially important where a supplier handles sensitive information and may influence future contracts, system expansion and public policy.

The source text contains no information about Palantir’s NHS involvement. It does not state a contract value, number of hospitals, number of staff or quantity of patient data. Supplying precise figures without a cited contract, NHS disclosure or audit would risk presenting uncertain information as fact.

A reliable scale assessment would separate several measures. Contract value should identify the period, options and included services. Hospital coverage should distinguish signed organisations from active deployments. Staff numbers should specify registered, trained or regular users. Data volume should explain whether it means patients, records, events or datasets, since these are not interchangeable.

The NHS should publish those definitions alongside procurement documents and deployment reports. Independent reviewers could then reconcile supplier statements with invoices, user logs, implementation records and data-governance documentation. This would show not only how large the arrangement is, but also whether the scale is justified by outcomes. The supplied article provides none of that evidence.

If an independent review confirms Palantir’s benefits, NHS bodies could have stronger grounds for continuing or expanding deployments. Procurement decisions might rely more heavily on measured outcomes, provided the review also finds acceptable costs, safeguards and interoperability. Clear evidence could reassure staff and the public that the technology is delivering more than a persuasive sales narrative.

If the review challenges the claims, the NHS might require corrective work, renegotiate contracts, pause expansion or consider competing suppliers. It could also change evaluation rules so future projects require stronger baselines, open methods and published results. A negative finding would not automatically prove that every Palantir deployment fails, but it would demand a more careful examination of local outcomes.

In both cases, transparency is central. The supplied article does not discuss this NHS issue, so it offers no reported outcome. Public trust will depend on explaining what data were used, who conducted the review, what limitations existed and how decision-makers responded to the findings.

An alternative assessment could come from an independent university research team, a public-sector audit body, an NHS evaluation unit or a specialist technology auditor. These organisations should have contractual access to the necessary data and freedom to publish their methods and findings. The supplied article does not identify any specific reviewer or alternative provider.

Commercial comparison is also possible. Other healthcare-data and enterprise-software companies could demonstrate competing systems against the same requirements. However, a rival vendor would have its own commercial interest, so its evidence should receive the same scrutiny. Useful methods include controlled pilots, matched-site comparisons, interrupted time-series analysis, cost-effectiveness studies, security testing and audits of data access.

The best approach is a mixed one. Independent researchers can analyse outcomes, auditors can inspect spending and governance, technical testers can examine security, and NHS staff can assess usability. Results should be checked against patient and workforce experience. No single company should define success, choose every measure or control all the evidence.

An organisation should begin by defining success before buying or deploying the software. Measures should cover outcomes, cost, safety, security, privacy, interoperability and staff experience. Baseline data and comparison groups must be preserved, so later changes can be attributed fairly rather than credited automatically to the supplier.

The evaluation should be designed by people independent of the vendor and, where possible, preregistered or publicly documented. Auditors and researchers need access to relevant records, including failures and unchanged outcomes. The organisation should test the system in stages, compare it with realistic alternatives and separate software effects from staffing, policy or demand changes.

Commercial incentives do not prove that a supplier’s claims are false. They do mean the claims require verification. Contracts should include audit rights, data-access rules, measurable milestones, exit provisions and publication duties. The supplied article does not address Palantir, so this framework is general guidance based on established evaluation practice.